Risk factors for subtherapeutic levels of posaconazole tablet | Zendy

Laura Tang | Zendy; Bernard L. Marini | Zendy; Lydia L. Benitez | Zendy; Jerod Nagel | Zendy; Marisa H. Miceli | Zendy; Caroline Berglund | Zendy; Anthony J. Perissinotti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk factors for subtherapeutic levels of posaconazole tablet

Author(s) -

Laura Tang,

Bernard L. Marini,

Lydia L. Benitez,

Jerod Nagel,

Marisa H. Miceli,

Caroline Berglund,

Anthony J. Perissinotti

Publication year - 2017

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkx228

Subject(s) - posaconazole , medicine , pharmacology , biology , microbiology and biotechnology , antifungal , voriconazole

Posaconazole is the prophylactic antifungal of choice for patients with haematological malignancies at high risk of invasive fungal infections (IFIs). Studies have demonstrated that subtherapeutic concentrations of posaconazole are associated with breakthrough fungal infections and specific risk factors for subtherapeutic troughs associated with the suspension formulation have been identified. However, these risk factors have not been evaluated in a large patient population with the recently approved tablet formulation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research